Company profile
Alvotech
Pipeline14 assets
- High-concentration, low-volume adalimumabAVT02 / HUMIRA® / Biosimilar / ImmunologyBiosimilar to HUMIRA®ApprovedApprovedU.S.Europe (EEA, UK, Switzerland, Balkans)CanadaAustraliaSaudi ArabiaIsraelEgyptSouth AfricaMoroccoPeruBolivia
- ustekinumabAVT04 / STELARA® / Biosimilar / ImmunologyBiosimilar to STELARA®ApprovedApprovedU.S.JapanCanadaEU/EEA
- denosumabAVT03 / PROLIA®/XGEVA® / Biosimilar / Bone DiseaseBiosimilar to PROLIA®/XGEVA®ApprovedApprovedJapanEU/EEA
- golimumabAVT05 / SIMPONI®/SIMPONI ARIA® / Biosimilar / ImmunologyBiosimilar to SIMPONI®/SIMPONI ARIA®ApprovedApprovedJapanEU/EEAUnited Kingdom
- afliberceptAVT06 / EYLEA® / Biosimilar / OphthalmologyBiosimilar to EYLEA®ApprovedApprovedEU/EEAJapanUnited Kingdom
- omalizumabAVT23 / XOLAIR® / Biosimilar / Respiratory
- vedolizumabAVT16 / ENTYVIO® / Biosimilar / Immunology
- pembrolizumabAVT33 / KEYTRUDA® / Biosimilar / Oncology
- certolizumab pegolAVT10 / CIMZIA® / Biosimilar / Immunology
- ixekizumabAVT28 / TALTZ® / Biosimilar / Immunology
- canakinumabAVT48 / ILARIS® / Biosimilar / Immunology
- guselkumabAVT41 / TREMFYA® / Biosimilar / Immunology
- ofatumumabAVT65 / KESIMPTA® / Biosimilar / Immunology
- dupilumabAVT19 / DUPIXENT® / Biosimilar / Immunology
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.